New Clinical Targets for Improving the Outcome of Schizophrenia

Stephen R. Marder, MD

Introduction

Stephen R. Marder, M.D. is the Daniel X. Freedman Professor of Psychiatry, the Vice Chair for Education, and the Director of the Section on Psychosis at the UCLA Semel Institute for Neuroscience and Human Behavior.  He is also the Director of the VISN 22 Mental Illness Research, Education Clinical Center (MIRECC) for the Department of Veterans Affairs.  Dr. Marder received his AB from the University of Pennsylvania and his MD from the State University of New York in Buffalo.   He completed an Internship at Denver General Hospital and a Psychiatry Residency at the University of Southern California.   This was followed by two years of research training at the National Institute of Mental Health (NIMH) Clinical Center.  Dr. Marder’s research has focused on improving the lives of individuals with psychotic disorders, particularly schizophrenia.   His research --  supported by the VA, the Brain and Behavior Research Foundation, and the National Institute of Mental Health -- has focused on the development of pharmacological,  psychosocial, and rehabilitation approaches for improving functioning and quality of life.  He led the NIMH MATRICS (Management and Treatment Research to Improve Cognition in Schizophrenia) initiative which provided guidance for the development of pharmacologic agents to improve cognition and motivation in schizophrenia.  He also led an NIMH Network for trials of medications for improving cognition in schizophrenia.   From 2016 to 2018 he was the President of the International Society of CNS Clinical Trials and Methodology.   He is considered an expert on clinical trials methods for complex CNS disorders, particularly schizophrenia.  Dr. Marder has received the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill, the Stanley Dean Research Award of the American College of Psychiatry, the Alexander Gralnick Award from the American Psychiatric Association, the Kempf Award from the American Psychiatric Association, the American Psychiatric Association Award for Research, the Wayne Fenton Award for Outstanding Clinical Care from the Schizophrenia Bulletin, and the Lieber Prize for Schizophrenia Research.  He is listed in The Best Doctors in America and America's Top Doctors.

Learning Objectives

1. Describe the schizophrenia symptoms that are related to imparied functioning.

2. Describe the social processing domains that are impaired in schizophrenia.

3. Describe the impairments in neural plasticity that are found in schizophrenia.

Live webcast available at: http://videos.mayo.edu/live
1 AMA PRA Category 1 Credit(s)™ hour is offered for watching this Webcast live. Ethos will be implemented for all post presentation surveys. To document your attendance, please text the code given at the presentation to 507-200-3010. For questions, email rstpsychgr@mayo.edu.

Accreditation Statement

In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s)

AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

APA
The Department of Psychiatry and Psychology at Mayo Clinic, Rochester, is approved by the American Psychological Association to sponsor continuing education credits for psychologists. The Department of Psychiatry and Psychology at Mayo Clinic, Rochester maintains responsibility for this program and its content.

Archived webcast available at: Psychiatry & Psychology Video Library

Industry Acknowledgment (if applicable): None.

All participants MUST complete the evaluation in order to get CME or APA Credit.

1) Text the CODE announced at the session within 48 hours to (507) 200-3010
2) Login at ce.mayo.edu and go to My Account, My Courses, Registered Courses, click Session title and START to access the required Evaluation.
-or-
Click the START button on that session page.
3) Evaluation must be completed within 2 weeks.

Disclosure Summary
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.
 

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry:

Mark Frye, M.D. - Mayo Clinic

Grant Support: AssureRx, Janssen R&D, Myriad, Pfizer Consultant: Janssen R&D, Mitsubishi Tanabe Pharma Corp., Myriad Genetics, Sunovion, Supernus Pharmaceuticals, Teva Pharmaceuticals, Neuralstem, Inc.

CME/Travel: American Physician Institute, CME Outfitters

Speaker:  Stephen R. Marder, M.D.

Consultant:  Abbvie, Roche, Teva, Newron, Otsuka, Lundbeck

Grant/Research Support:  Takeda, Boeringer Ingelheim

No relevant financial relationship(s) with industry:
Kriti Gandhi, M.D., Allison Holgerson, Ph.D., Matej Markota, M.D., Charlene Nelson, Reem Shafi, M.B.B.S., Larua Suarez, M.D.

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:

Speaker:  Stephen R. Marder, M.D.

Oxytocin